To study the effect of gene dose alterations on the cellular proteome, we carried out a proteomic investigation on murine embryonic stem cells that either overexpressed individual genes or displayed aneuploidy over a genomic region encompassing 14 genes.
9– 11 Renal impairment does not require dose alterations.
Approval from the DSMC will be required prior to any subsequent dose alterations.
This will allow us to track changes in medication instruction, such as swapping to 16 hour use or dose alterations.
Plasma clearance of paclitaxel exhibits non-linear kinetics, which results in a disproportionate change in plasma concentration and area under the concentration time curve with dose alterations.
With an increasing cumulative dose, alterations to myocyte ultrastructure may progress further towards end-stage degeneration and cell death (Billingham et al, 1978; Von Hoff et al, 1979).
Dabigatran and edoxaban do not require any dose alterations in the first weeks of therapy and may provide a simpler approach after patient discharge, but the need for a minimum of 5 days of injectable therapy may not be desirable.
These dose alterations span variable sizes, ranging from 210 Kb to 13.4 Mb, which altogether represent almost 83 Mb of non-overlapping genomic sequence, or about 2.67% of the human genome.
